Shares of BioAge Labs, Inc. (NASDAQ:BIOA – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $29.00.
Several research firms have weighed in on BIOA. Citigroup dropped their target price on BioAge Labs from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday. Wall Street Zen cut shares of BioAge Labs from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 10th. Weiss Ratings upgraded BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. BTIG Research reiterated a “buy” rating on shares of BioAge Labs in a report on Monday, November 9th. Finally, Jefferies Financial Group set a $21.00 target price on BioAge Labs in a research note on Friday, July 31st.
View Our Latest Analysis on BioAge Labs
BioAge Labs Trading Down 1.3%
Shares of BIOA opened at $4.71 on Friday. The firm has a market cap of $216.47 million, a P/E ratio of -1.85 and a beta of 1.19. BioAge Labs has a 12-month low of $4.45 and a 12-month high of $25.95. The company’s 50-day moving average price is $6.26 and its 200 day moving average price is $14.85.
BioAge Labs (NASDAQ:BIOA – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.05). BioAge Labs had a negative return on equity of 31.42% and a negative net margin of 1,253.60%. The company had revenue of $0.30 million for the quarter. Equities research analysts forecast that BioAge Labs will post -2.59 earnings per share for the current year.
Hedge Funds Weigh In On BioAge Labs
Institutional investors and hedge funds have recently made changes to their positions in the stock. a16z Capital Management L.L.C. purchased a new stake in shares of BioAge Labs during the third quarter worth approximately $22,923,000. BlackRock Inc. purchased a new stake in shares of BioAge Labs during the 2nd quarter worth $69,831,000. Jupiter Topco LLC acquired a new position in shares of BioAge Labs during the second quarter worth $52,597,000. Janus Henderson Group PLC grew its stake in shares of BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after purchasing an additional 1,685,063 shares in the last quarter. Finally, Octagon Capital Advisors LP increased its holdings in BioAge Labs by 9.4% in the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after buying an additional 150,000 shares during the last quarter.
About BioAge Labs
BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.
Recommended Stories
- Five stocks we like better than BioAge Labs
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.
